Tag: GLP-1/GIP receptor agonist
Viking Therapeutics’ obesity drug VK2735 could rival Eli Lilly’s Tirzepatide, says...
New Phase IIa results reveal significant weight loss, positioning VK2735 as a potential market leader amid increasing competition